BG
ATRA icon

BlackRock Group’s Atara Biotherapeutics ATRA Stock Holding History

BlackRock Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$86K Buy
240
+19
+9% +$8.04K ﹤0.01% 2854
2016
Q3 		$119K Buy
221
+8
+4% +$4.34K ﹤0.01% 2784
2016
Q2 		$121K Sell
213
-3
-1% -$1.44K ﹤0.01% 2727
2016
Q1 		$103K Buy
216
+94
+77% +$42.3K ﹤0.01% 2755
2015
Q4 		$80K Sell
122
-4
-3% -$3.03K ﹤0.01% 2741
2015
Q3 		$99K Buy
126
+44
+54% +$53.7K ﹤0.01% 2710
2015
Q2 		$109K Buy
+82
New +$94.1K ﹤0.01% 2729

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Group's ATRA Position: Q4 2016 in Review

BlackRock Group increased its Atara Biotherapeutics (ATRA) stake by 8.6% in Q4 2016, buying an estimated $8.04K and bringing the position to 240 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

BlackRock Group first reported a position in ATRA in Q2 2015 and has held it in 7 quarters since. The position peaked at $121K in Q2 2016. 86 funds tracked by Wall St. Rank hold ATRA as of Q4 2016.

  • BlackRock Group held 240 shares of Atara Biotherapeutics worth $86K as of Q4 2016.
  • BlackRock Group bought 19 Atara Biotherapeutics shares in Q4 2016, an estimated $8.04K.
  • Atara Biotherapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2854 holding.
  • BlackRock Group first reported a position in Atara Biotherapeutics in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Group's Atara Biotherapeutics position peaked at $121K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.